AI-powered evaluation using the Model Context Optimization BS Detection Framework, based solely on publicly available website content.
Based on 784 businesses audited.
Medical Devices, Pharma & Biotech BS: Tresiba (Novo Nordisk) (tresiba.com)
This is a high-substance, low-BS site driven by stringent pharmaceutical regulatory requirements. It prioritizes safety documentation and technical dosing data over marketing hyperbole.
To further reduce the BS score, the site should update the MMIT formulary data which is currently over 24 months old. They should replace the emotive hero heading Find your reason with a more outcome-oriented metric. Finally, adding inline citations for the powerful A1C reduction claim would bridge the small gap between marketing and clinical proof.
The site exhibits high substance-to-fluff ratios, specifically in the detailed dosing instructions and molecular explanations. Specific nouns and technical specifications like 100 Units per mL and 200 Units per mL concentrations and the 8-hour minimum interval between doses provide high density. Some points were lost for repetitive value propositions regarding 24-hour management and the emotive hero heading Find your reason for managing your blood sugar which lacks a specific metric.
When your heading hierarchy collapses, AI cannot determine where one idea ends and the next begins. Run a Semantic HTML Machine Readability Audit to see how your structure is actually chunked by LLMs.
There is virtually zero semantic drift between the homepage signal and sub-page delivery. The homepage H1 focuses on Safety Information, which is meticulously detailed across all sub-pages, and the hero promise of long-acting insulin is technically substantiated on the About Tresiba page through the string of pearls molecular design explanation. Messaging remains consistent for both adults and pediatric patients over 1 year of age across the entire sitemap.
Our Authority as a Service model transforms raw diagnostic data into high stakes results. Start your Clinical Strategic Diagnosis for 1 Euro to secure the strategic fixes required for growth.
The site avoids trust theatre entirely, with a review_count of 0 and no unverified patient testimonials. Trust is established through high-authority proof paths, including direct links to FDA MedWatch and the full Prescribing Information PDF. A minor penalty of 1 point was applied in the Trust and Proof pillar because the formulary data mentioned on the Savings page is dated February 2024, which is 28 months stale relative to the June 2026 system date.
The proof density is high, featuring specific regulatory-required evidence such as the 100 U per mL and 200 U per mL concentrations and step-by-step instructions for the FlexTouch pen. Verifiable evidence outweighs vague assertions, with only a few marketing phrases like powerful reduction lacking an immediate inline clinical citation, though they are supported by the linked PI.
To evaluate URL identity stability and multilingual coherence, review the Yoast Identity Stability audit. View the Yoast Identity Stability Audit for a practical example of canonical alignment and language layer integrity.
While the site uses industry clichés such as powerful A1C reduction and works the way the body’s insulin does, these are largely regulatory-approved descriptions rather than empty marketing. The commodity fingerprint is reduced by the specific molecular differentiation of insulin degludec. However, template sections like Support and Resources and the use of actor portrayal labels are standard pharma boilerplate.
Authority is robustly supported by the schema_json, which correctly identifies the page as a MedicalWebPage with Drug and MedicalCondition properties. The manufacturer, Novo Nordisk, is clearly identified with links to its affordability programs at NovoCare.com. No individual experts are named, but the authority is deferred to the FDA and healthcare providers, which is standard and credible for this industry.
There is no disconnect between marketing tone and clinical demonstration. Claims of around-the-clock management are backed by technical descriptions of how the insulin releases slow and steady from its molecular chain. The site does not over-promise; it balances every efficacy claim with a corresponding safety warning as required by law.
Medical Devices, Pharma & Biotech BS: Tresiba (Novo Nordisk) (tresiba.com)
The site perfectly aligns with the Pharma and Biotech category, utilizing mandatory regulatory frameworks and clinical terminology. The presence of comprehensive Important Safety Information (ISI) and Prescribing Information (PI) links confirms its status as a highly regulated medical product site.
The access layer decides whether your content even enters the model's world. Review the Crawlability & Indexation Framework to see how AI visible content differs from what humans see in the browser.
“The score of 15 is exceptionally low, driven primarily by the high information density and lack of semantic drift. The few points accrued came from aging formulary data in the Trust pillar and standard industry clichés in the Commodity Fingerprint pillar. The site serves as a benchmark for substance in a regulated industry.”